The study highlights how the IntelliSep sepsis test empowers clinicians to identify sepsis earlier—often before traditional clinical criteria are met—and avoid overtreatment of patients unlikely to benefit from sepsis interventions. The study assessed the impact of integrating IntelliSep into clinical and documentation workflows on SEP-1 compliance using data from 598 patients discharged with sepsis ICD-10 codes. OLOL, a high-performing hospital already exceedingnational SEP-1 compliance benchmarks, reported a 28.9% relative increase in SEP-1 performance over a six-month period, rising from 61.2% in July 2024 to 78.9% in December 2024. "The clinical criteria for the SEP-1 bundle may not always support identification of sepsis early on in the progression of disease," said Dr. Hollis O'Neal, Medical Director of Research at OLOLRMC. For more details download the study, " Investigation of the Effect of Implementing a Host Response Test on SEP-1 Compliance ."